Fight Dependency

There’s good news for those people whose daily lives are overshadowed by MS. The race is lastly on to develop a more practical treatment for the illness between main drug manufactures. Merck has been in the process of testing their newest remedy Cladribine as a potential MS treatment. Their analysis has confirmed that sufferers who have undergone a short sequence of treatments with this new oral drug have a very high rate of success in achieving lower relapse rates when in comparison with many of the presently available medications for the disease like MS.

To emphasize the potential for Cladribine as a treatment for MS the producer offered a report to the European Committee for Treatment and Research in Multiple Sclerosis Congress. The results they offered showed involved a study group consisting of sufferers who took one of 2 different doses or a placebo. The results showed that forty three and 44 per cent of those taking the drug were found to be symptom free for a period of 2 full years. This was in comparison with only 16 per cent of those that were given the placebo.

Merck is presently working hard with the FDA to realize approval at the same time as their rivals at Biogen and Novartis are developing mediations and in search of approval. The general potential for Cladribine as an MS treatment is slightly overshadowed by a very slight threat of cancer in some patients. As this can be the primary oral treatment available for MS sufferers and as such could possibly be a potential blockbuster for the manufacturer.

One of many largest advantages of this remedy is for those in the late stage of multiple sclerosis are far less prone to end up being disabled. It has additionally been proven that this new drug may also help to reduce the chance of lesions developing. Based on many neurologists the potential for Cladribine as an MS treatment far outweighs any recognized dangers and in reality they are way more more likely to prescribe this new drug for his or her sufferers in any part of the illness over the medicines being developed by both Novartis or Biogen.

Regardless of which set of tests you look at the numbers coming back present the definite potential of Cladribine as a treatment for MS. Sufferers who have waited years for a truly effective treatment are anxiously awaiting approval of this new remedy and are praying that the FDA doesn’t drag their feet. That is the primary new remedy to return along in a few years to show this kind of potential and anticipation is high in both the medical community and sufferers alike.

If you enjoyed this post, make sure you subscribe to my RSS feed!

Tags: cure, health, medical, natural remedy, treatment